Table 2. Polyvalent testing (HIV-1 EID, HIV-1 VL and MTB/RIF) profiles at the three study sites.
| GMH | MMH | CRHC | |
|---|---|---|---|
| Decentralized Xpert HIV-1 Qual | |||
| Total tested | 139 | 80 | 58 |
| Positivity rate | 2.20% | 2.50% | 12.10% |
| Error rate | 2.90% | 1.40% | 3.40% |
| ¤Median days to result delivery to clinician [IQR] | 1 [0–3] | 8 [6–12] | 1 [0–1] |
| Result concordance with centralized EID testing | 100% | 100% | 98.20% |
| Distance from centralized lab | 275km | 180km | 300km |
| Conventional centralized EID testing | |||
| Median days to result delivery to clinician [IQR] | 14 [12–16] | 21 [17–30] | 20 [17–23] |
| Decentralized Xpert HIV-1 Quant | |||
| Total tested | 640 | 417 | 245 |
| §Viral load detectability rate | 11.40% | 5.90% | 9.30% |
| Error rate | 3.70% | 3.60% | 3.70% |
| Median days to result delivery clinician [IQR] | 1 [0–1] | 1 [0–2] | 0 [0–1] |
| *Result concordance with centralized VL testing | 98.20% | 98.50% | 96.80% |
| Distance from centralized lab | 240km | 250km | 265km |
| Conventional centralized VL testing | |||
| Median days to result delivery to clinician [IQR] | 24 [23–29] | 27 [24–31] | 34 [24–45] |
| Xpert MTB/Rif | |||
| Total samples tested | 438 | 1028 | 115 |
| Positivity rate | 10.60% | 9.60% | 11.30% |
| Rif positivity rate | 0.50% | 0.58% | 0 |
| Error rate | 3.40% | 1.90% | 2.60% |
| Median days to result delivery to clinician [IQR] | 1 [0–1] | 1 [0–2] | 0 [0–1] |
| Average polyvalent cartridges spent per month on a 4 modular machine | 121 | 153 | 42 |
| GeneXpert utilization rate¥ | 50.40% | 63.50% | 17.50% |
§VL detectability rate = VL ≥1000 copies/mL
¤ Median days to results to the clinician at the facility with the GeneXpert instrument
*Result concordance estimated at the 1000 copies/mL threshold
¥ Estimates based on calculations that one 4-module GeneXpert device has capacity to process 3,000 tests per year.
GMH-district lab; MMH-district referral lab, CRHC-Microscopy site lab